{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:13:43Z","timestamp":1793106823929,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,2,20]]},"DOI":"10.1038\/s41416-025-03285-x","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:03:46Z","timestamp":1765807426000},"page":"598-607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent\/metastatic nasopharyngeal carcinoma: a retrospective cohort study"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-0061","authenticated-orcid":false,"given":"Shui-Qing","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8801-3660","authenticated-orcid":false,"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1004-4464","authenticated-orcid":false,"given":"Ze-Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Qing","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hui","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9132-0805","authenticated-orcid":false,"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8726-3134","authenticated-orcid":false,"given":"Wei-Xin","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-3794","authenticated-orcid":false,"given":"Yan-Qun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1053-7050","authenticated-orcid":false,"given":"Guo-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"3285_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64\u201380.","journal-title":"Lancet"},{"key":"3285_CR2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. New Engl J Med. 2019;381:1124\u201335.","journal-title":"New Engl J Med"},{"key":"3285_CR3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jama.2022.13997","volume":"328","author":"LL Tang","year":"2022","unstructured":"Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, et al. Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial. Jama. 2022;328:728\u201336.","journal-title":"Jama"},{"key":"3285_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","volume":"398","author":"YP Chen","year":"2021","unstructured":"Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398:303\u201313.","journal-title":"Lancet"},{"key":"3285_CR5","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/cncr.30520","volume":"123","author":"H Peng","year":"2017","unstructured":"Peng H, Chen L, Li WF, Guo R, Mao YP, Zhang Y, et al. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a randomized phase 3 clinical trial. Cancer. 2017;123:1643\u201352.","journal-title":"Cancer"},{"key":"3285_CR6","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1200\/JCO.21.00396","volume":"39","author":"S Hong","year":"2021","unstructured":"Hong S, Zhang Y, Yu G, Peng P, Peng J, Jia J, et al. Gemcitabine Plus Cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 Phase III Study. J Clin Oncol. 2021;39:3273\u201382.","journal-title":"J Clin Oncol"},{"key":"3285_CR7","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"HQ Mai","year":"2023","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. Jama. 2023;330:1961\u201370.","journal-title":"Jama"},{"key":"3285_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell. 2023;41:1061\u201372.e4.","journal-title":"Cancer Cell"},{"key":"3285_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","volume":"13","author":"G Bocci","year":"2016","unstructured":"Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016;13:659\u201373.","journal-title":"Nat Rev Clin Oncol"},{"key":"3285_CR10","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1172\/JCI8829","volume":"105","author":"G Klement","year":"2000","unstructured":"Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Investig. 2000;105:R15\u201324.","journal-title":"J Clin Investig"},{"key":"3285_CR11","first-page":"1878","volume":"60","author":"T Browder","year":"2000","unstructured":"Browder T, Butterfield CE, Kr\u00e4ling BM, Shi B, Marshall B, O\u2019Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878\u201386.","journal-title":"Cancer Res"},{"key":"3285_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.canlet.2017.01.040","volume":"400","author":"YL Chen","year":"2017","unstructured":"Chen YL, Chang MC, Cheng WF. Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Lett. 2017;400:282\u201392.","journal-title":"Cancer Lett"},{"key":"3285_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/cac2.12004","volume":"40","author":"XS Sun","year":"2020","unstructured":"Sun XS, Liu SL, Liang YJ, Chen QY, Li XY, Tang LQ, et al. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: a propensity score matching study. Cancer Commun. 2020;40:32\u201342.","journal-title":"Cancer Commun"},{"key":"3285_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-024-00621-3","volume":"25","author":"Q He","year":"2024","unstructured":"He Q, Luo X, Liu L, Zhao C, Li Z, Jin F. Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma. BMC Immunol. 2024;25:28.","journal-title":"BMC Immunol"},{"key":"3285_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jamaoncol.2021.7366","volume":"8","author":"GY Liu","year":"2022","unstructured":"Liu GY, Li WZ, Wang DS, Liang H, Lv X, Ye YF, et al. Effect of capecitabine maintenance therapy plus best supportive care vs best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy: a phase 3 randomized clinical trial. JAMA Oncol. 2022;8:553\u201361.","journal-title":"JAMA Oncol"},{"key":"3285_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","volume":"7","author":"E Pasquier","year":"2010","unstructured":"Pasquier E, Kavallaris M, Andr\u00e9 N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455\u201365.","journal-title":"Nat Rev Clin Oncol"},{"key":"3285_CR17","first-page":"E5226","volume":"114","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Sun M, Huang G, Yin L, Lai Q, Yang Y, et al. Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy. Proc Natl Acad Sci USA. 2017;114:E5226\u2013e35.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3285_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/01.mph.0000183863.10792.d4","volume":"27","author":"MW Kieran","year":"2005","unstructured":"Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol\/Oncol. 2005;27:573\u201381.","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"3285_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","volume":"358","author":"I Kareva","year":"2015","unstructured":"Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015;358:100\u20136.","journal-title":"Cancer Lett"},{"key":"3285_CR20","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1158\/1078-0432.CCR-05-0437","volume":"11","author":"RJ Epstein","year":"2005","unstructured":"Epstein RJ. Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment. Clin Cancer Res. 2005;11:5337\u201341.","journal-title":"Clin Cancer Res"},{"key":"3285_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110311","volume":"196","author":"Y Liu","year":"2024","unstructured":"Liu Y, Ma J, Zeng XY, Zuo ZC, Chen RZ, Li XY, et al. Efficacy of metastatic lesion radiotherapy in patients with metastatic nasopharyngeal carcinoma: a multicenter retrospective study. Radiother Oncol. 2024;196:110311.","journal-title":"Radiother Oncol"},{"key":"3285_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221112486","volume":"14","author":"MX Zhang","year":"2022","unstructured":"Zhang MX, Liu T, You R, Zou X, Liu YL, Ding X, et al. Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective study. Ther Adv Med Oncol. 2022;14:17588359221112486.","journal-title":"Ther Adv Med Oncol"},{"key":"3285_CR23","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1002\/cam4.2926","volume":"9","author":"H Zhou","year":"2020","unstructured":"Zhou H, Lu T, Guo Q, Chen Y, Chen M, Chen Y, et al. Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma. Cancer Med. 2020;9:2732\u201341.","journal-title":"Cancer Med"},{"key":"3285_CR24","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.2147\/CMAR.S234271","volume":"12","author":"Q Guo","year":"2020","unstructured":"Guo Q, Chen M, Xu H, Lu T, Zhou H, Chen Y, et al. Oral maintenance chemotherapy using S-1\/Capecitabine in metastatic nasopharyngeal carcinoma patients after systemic chemotherapy: a single-institution experience. Cancer Manag Res. 2020;12:1387\u201396.","journal-title":"Cancer Manag Res"},{"key":"3285_CR25","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1007\/s00432-022-04341-2","volume":"149","author":"Y Lu","year":"2023","unstructured":"Lu Y, Huang H, Yang H, Hu X, Liu M, Huang C, et al. Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study. J Cancer Res Clin Oncol. 2023;149:4327\u201338.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3285_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02790-1","volume":"21","author":"LQ Tang","year":"2023","unstructured":"Tang LQ, Li XY, Li ZM, Liu ZG, Lin MZ, Zhou H, et al. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and\/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial. BMC Med. 2023;21:94.","journal-title":"BMC Med"},{"key":"3285_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/1758834016637592","volume":"8","author":"P Peng","year":"2016","unstructured":"Peng P, Ou X, Liao H, Liu Y, Wang S, Cheng Z, et al. Phase II study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy. Ther Adv Med Oncol. 2016;8:153\u20139.","journal-title":"Ther Adv Med Oncol"},{"key":"3285_CR28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/path.5249","volume":"247","author":"WKJ Lam","year":"2019","unstructured":"Lam WKJ, Chan KCA, Lo YMD. Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker. J Pathol. 2019;247:641\u20139.","journal-title":"J Pathol"},{"key":"3285_CR29","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.7150\/jca.56397","volume":"12","author":"W Li","year":"2021","unstructured":"Li W, Yang C, Lv Z, Li J, Li Z, Yuan X, et al. Integrating pre- and post-treatment Plasma Epstein-Barr Virus DNA levels for better prognostic prediction of Nasopharyngeal Carcinoma. J Cancer. 2021;12:2715\u201322.","journal-title":"J Cancer"},{"key":"3285_CR30","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1002\/cncr.25932","volume":"117","author":"X An","year":"2011","unstructured":"An X, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic\/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011;117:3750\u20137.","journal-title":"Cancer"},{"key":"3285_CR31","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1200\/JCO.2000.18.6.1324","volume":"18","author":"A Fandi","year":"2000","unstructured":"Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol. 2000;18:1324\u201330.","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03285-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:55:05Z","timestamp":1769770505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03285-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,20]]}},"alternative-id":["3285"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03285-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective study was approved by Sun Yat-sen University Cancer Center (SYSUCC, IRB-approved number, SL-B2024-371). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}